<DOC>
	<DOCNO>NCT00974389</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , S-1 , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving S-1 together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give S-1 together bevacizumab work third-line therapy treat patient colorectal cancer recurrent remove surgery .</brief_summary>
	<brief_title>S-1 Bevacizumab Treating Patients With Colorectal Cancer That Recurrent Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate give S-1 bevacizumab see well work third-line therapy KRAS-mutation patient unresectable recurrent colorectal cancer . OUTLINE : Patients receive oral S-1 twice daily day 1-28 bevacizumab IV day 1 , 15 , 29 . Courses repeat every 42 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal carcinoma Inoperable , locally advanced , metastatic disease KRASmutated Concurrently receive treatment contain irinotecan oxaliplatin regimens unresectable recurrent colorectal cancer Measurable disease accord RECIST No moderate severe ascites pleural effusion require treatment No metastasis CNS PATIENT CHARACTERISTICS : ECOG performance status 02 White blood cell count &gt; 3,500/mm³ &lt; 12,000/mm³ Neutrophil count &gt; 1,500/mm³ Hemoglobin &gt; 9.0 g/dL Platelet count &gt; 100,000/mm³ Total bilirubin &lt; 1.5 mg/dL AST ALT &lt; 100 U/L ( &lt; 200 U/L patient liver metastasis ) Serum creatinine &lt; 1.2 mg/dL Creatinine clearance ≥ 50 mL/min Urine dipstick proteinuria &lt; 1+ INR &lt; 1.5 Not pregnant nursing Able take capsule orally No active second cancer No active infection ( e.g. , patient pyrexia ≥ 38°C ) No serious complication ( e.g. , pulmonary fibrosis , interstitial pneumonitis , heart failure , renal failure , hepatic failure , poorly control diabetes , hypertension ) No electrocardiographic abnormality cardiac disorder would clinically preclude execution study judge investigator No serious drug hypersensitivity history drug allergy No thrombosis , cerebral infarction , myocardial infarction , pulmonary embolism No history evidence inherit bleed diathesis coagulopathy risk bleed No clinically significant traumatic injury within past 4 week No severe mental disorder PRIOR CONCURRENT THERAPY : See Disease Characteristics Concurrent lowdose aspirin therapy ( &lt; 325 mg/day ) allow More 4 week since prior major surgical procedure open biopsy No prior therapy radiotherapy No prior therapy S1 No prior chemotherapy include irinotecan oxaliplatin first secondline treatment . No concurrent continuous treatment steroids No concurrent treatment flucytosine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>